Cellular Imaging and Molecular Pathology

细胞成像和分子病理学

• 批准号: 8260370
• 负责人: CHRISTOPHER H CONTAG
• 金额: $ 32.4万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8260370
• 关键词: Animal Model; Animals; Biological; Biological Assay; Biological Models; Biological Process; Bone Marrow Transplantation; Cell Line; Cell Transplantation; Cell physiology; Cells; Chemistry; Chromosomal translocation; Clinical; Custom; Data; Data Set; Detection; Diagnostic; Disease; Disease Progression; Early Diagnosis; Ensure; Gene Dosage; Gene Expression; Gene Rearrangement; Genes; Genetic Transcription; Goals; Hematopoietic; Image; Image Analysis; Imaging Device; Immune; Immunoglobulin Somatic Hypermutation; Investigation; Investigational Therapies; Kinetics; Label; Life; Magnetic Resonance Imaging; Methods; Molecular; Molecular Probes; Molecular Profiling; Monitor; Mutation; Patients; Pattern; Performance; Play; Population; Positron-Emission Tomography; Procedures; Process; Program Research Project Grants; Reagent; Recurrence; Relapse; Relative (related person); Reporter; Reporter Genes; Research Personnel; Residual Neoplasm; Resolution; Resources; Role; Scheme; Sequence Analysis; Services; Site; Specimen; System; Technology; Testing; Therapeutic; Time; Tissue Sample; Tissues; Treatment Protocols; Treatment outcome; Ultrasonography; Viral Genes; Virus Latency; Work; X-Ray Computed Tomography; base; burden of illness; cellular imaging; clinical care; in vivo; instrument; instrumentation; leukemia/lymphoma; meetings; member; migration; molecular imaging; molecular pathology; molecular/cellular imaging; multimodality; novel; optical imaging; pre-clinical; preclinical study; programs; research clinical testing; response; single photon emission computed tomography; tool; trafficking; tumor growth; vector; whole body imaging

The role of the Cellular Imaging and Molecular Pathology Core is to support investigators in the Program Project Grant by providing a set of dedicated molecular biological and state-of-the-art in vivo molecular imaging analyses. Together these comprise the necessary tools for effective assessment of disease states, the molecular basis of response to therapy both in patients and in animal models and the analysis of the in vivo fate of cellular populations. The services provided by this Core are those that extend beyond routine preclinical studies and standard clinical care. This Core provides molecular testing for projects that monitor treatment outcomes, detect early disease recurrence and minimal disease states. Rapid and quantitative assessment of experimental therapies is necessary for accelerated and accurate analyses of potential efficacy. We have developed molecular imaging tools for such analyses in living animal models and these will be used to study and optimize the therapies proposed in this program. An established Small Animal Imaging Core Resource at Stanford provides the instrumentation and expertise for these investigations and will continue to refine the methods for specific programmatic applications and move toward clinical imaging strategies. In vivo molecular imaging will be used to direct the ex vivo assays for more meaningful comprehensive analyses. In vivo imaging strategies utilizing novel bioluminescent markers which allow for the quantitative, noninvasive detection of disease burden and tracking of cellular populations will be used in Projects 3, 4, 5, 7 and 8. Molecular testing for disease specific chromosomal translocations or transcription products will be performed for Projects 1, 2 and 8 on leukemia and lymphoma specimens. Quantitative assessment of minimal residual disease will be performed using TaqMan chemistry for a robust assessment of disease response and potential recurrence on clinical specimens. The centralized performance of the molecular procedures by this Core will avoid duplication of efforts in the program and ensure timely, efficient and consistently high quality results. This combination of in vivo and ex vivo analyses strengthens the studies by providing more data and directed evaluation of clinical and preclinical specimens in a centralized core.

细胞成像和分子病理学核心的作用是支持该计划的研究人员 通过提供一套专用的分子生物学和最先进的体内分子生物学技术， 图像分析这些共同构成了有效评估疾病状况的必要工具， 在患者和动物模型中对治疗反应的分子基础，以及对这些反应的分析。 细胞群体的体内命运。此核心提供的服务超出常规 临床前研究和标准临床护理。该核心为监测项目提供分子检测 治疗结果，检测早期疾病复发和最小疾病状态。快速定量 对实验疗法的评估对于加速和准确分析潜在的 功效我们已经开发了分子成像工具，用于活体动物模型的此类分析， 将用于研究和优化本计划中提出的治疗方法。一种小动物 斯坦福大学的成像核心资源为这些调查提供了仪器和专业知识， 将继续改进特定程序应用的方法，并向临床成像方向发展 战略布局体内分子成像将用于指导离体测定，以获得更有意义的结果。 综合分析。利用新型生物发光标记物的体内成像策略， 疾病负荷的定量、非侵入性检测和细胞群的跟踪将用于 项目3、4、5、7和8。疾病特异性染色体易位或转录的分子检测 将对项目1、2和8的白血病和淋巴瘤标本进行产品检测。定量 将使用TaqMan化学进行微小残留病评估，以进行稳健评估 临床标本上的疾病反应和潜在复发。的集中表现， 该核心的分子程序将避免计划中的重复工作，并确保及时、有效地 和始终如一的高质量结果。体内和离体分析的这种组合加强了对细胞的免疫。 通过集中提供更多数据和指导临床和临床前样本的评价， 核心